News
MDWD
16.72
+0.78%
0.13
Weekly Report: what happened at MDWD last week (0923-0927)?
Weekly Report · 4d ago
Weekly Report: what happened at MDWD last week (0916-0920)?
Weekly Report · 09/23 12:06
Mediwound’s Growth Potential Bolstered by FDA Approval and Strategic Global Partnerships
TipRanks · 09/17 08:15
Weekly Report: what happened at MDWD last week (0909-0913)?
Weekly Report · 09/16 11:53
Weekly Report: what happened at MDWD last week (0902-0906)?
Weekly Report · 09/09 12:07
Weekly Report: what happened at MDWD last week (0826-0830)?
Weekly Report · 09/02 12:11
MediWound files to sell 1.45M ordinary shares for holders
Seeking Alpha · 08/29 20:52
MEDIWOUND LTD FILES FOR RESALE OF UP TO 1.45 MLN ORDINARY SHARES BY SELLING SHAREHOLDERS - SEC FILING
Reuters · 08/29 20:46
Weekly Report: what happened at MDWD last week (0819-0823)?
Weekly Report · 08/26 12:08
Mediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market Potential
TipRanks · 08/21 18:25
Weekly Report: what happened at MDWD last week (0812-0816)?
Weekly Report · 08/19 11:50
MediWound receives pediatric indication for burn treatment NexoBrid
Seeking Alpha · 08/18 16:49
Mediwound: Report of foreign issuer
Press release · 08/15 21:15
BUZZ-Vericel, MediWound climb on FDA's expanded approval for skin treatment
Reuters · 08/15 20:59
MediWound’s NexoBrid Gains FDA Pediatric Approval
TipRanks · 08/15 20:47
MediWound Says FDA Approves NexoBrid for Pediatric Burn Patients
Dow Jones · 08/15 20:45
MEDIWOUND ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL OF NEXOBRID® FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH SEVERE THERMAL BURNS
Reuters · 08/15 20:15
MediWound Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 08/15 12:08
Buy Rating Justified by MediWound’s Strong Financials and Product Expansion Potential
TipRanks · 08/15 10:18
Buy Rating Affirmed for Mediwound Amid Market Expansion and Positive Growth Prospects
TipRanks · 08/14 21:05
More
Webull provides a variety of real-time MDWD stock news. You can receive the latest news about Mediwound through multiple platforms. This information may help you make smarter investment decisions.
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.